Future Diagnostics performs pre-feasibility studies for third parties within the global medical technology and IVD market. These pre-feasibility studies are performed on different types of raw materials or assays. It can also be done on a variety of technologies and analyzers, both immunologically or molecular based. Have a look at our presentation on Slideshare
This week we are proud to be celebrating the 20th Anniversary of Future Diagnostics. We take this opportunity to thank all our employees, customers, partners and other stakeholders for their loyalty and helping us succeed.
We will re-open on Friday, May 26th.
VALENCIA, SPAIN, March 2017: Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain […]
“Biological materials have a mind of their own” AroCell’s research and development staff members started a valuable collaboration with Future Diagnostics in the Netherlands in 2011, for the development of the TK 210 ELISA test throughout all these different phases. Collaboration between AroCell team members and this extended contract assay development organization has led to […]
According to IVD companies, the market for near-patient testing is growing significantly. Diagnosis by Point-of-Care testing accelerates patient care decision-making and fast-tracks the time to initiate treatment. Because of the complexity, regulatory guidelines and the complicated set-up of POC platforms the growth potential is limited. Talking to our scientists, I learned about the complex decisions that have to […]
Future Diagnostics and DIAsource received a grant of 1.4m Euro from Eurostars (European Commission) Grant supports demonstration clinical utility and obtaining CE marking of the world’s first assay to measure Free Vitamin D Future Diagnostics Solutions (Wijchen, The Netherlands) and DIAsource Immunoassays SA, part of the Anteo Group (ASX: ADO), are pleased to announce that […]
Free 25OH Vitamin D seems to be a better marker of Vitamin D status than Total 25OH Vitamin D. Learn more about this topic at: 6th International Conference on Vitamin D deficiency Nutrition and Human Health in Abu Dhabi, United Arab Emirates from March 9th to 10th, 2017 This year’s meeting will focus on the […]
Future Diagnostics helps companies to accelerate the development of point-of-care tests in order to get the products faster to market. Companies can win time by outsourcing total developments, the (pre-)feasibility phase or finalizing the regulatory documents for the design history file, while their R&D can focus on other activities. Have a look at our presentation on […]
FDA Inspection Future Diagnostics Solutions B.V. is proud to announce the successful completion of its fourth Food and Drug Administration (FDA) inspection. The inspection confirmed the site to be compliant with the principles and guidelines of current Good Manufacturing Practices (cGMP) and zero Form 483 observations were issued. Mike Martens, Managing Director of Future Diagnostics, […]